Skip To Main Content
Barbara Sennino on Muck Rack

Barbara Sennino

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barbara

Contact Barbara, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms

|
By Minah Kim, Maximilian Nitschké, Barbara Sennino, Patrizia Murer
| cancerres.aacrjournals.org
Tumor Biology and Immunology Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms Minah Kim, Maximilian Nitschké, Barbara Sennino, Patrizia Murer, Brian J. Schriver, Alexander Bell, Aishwarya Subramanian, Corry E. McDonald, Jiahu Wang, Howard Cha, Marie-Claude Bourgeois-Daigneault, David H. Kirn, John C. Bell, Naomi De Silva, Caroline J. Breitbach and Donald M. McDonald
Open in Who Shared Issue with article?

Amplification of oncolytic vaccinia virus widespread tumor cell killing by sunitinib through multiple mechanisms

|
By Barbara Sennino, Minah Kim, Maximilian Nitschké, Patrizia Murer
| cancerres.aacrjournals.org
Amplification of oncolytic vaccinia virus widespread tumor cell killing by sunitinib through multiple mechanisms Minah Kim, Maximilian Nitschké, Barbara Sennino, Patrizia Murer, Brian J. Schriver, Alexander M. Bell, Aishwarya Subramanian, Corry E. McDonald, Jiahu Wang, Howard Cha, Marie-Claude Bourgeois-Daigneault, David H. Kirn, John C. Bell, Naomi De Silva, Caroline J. Breitbach and Donald M McDonald Cancer Res December 19 2017 DOI: 10.1158/0008-5472.CAN-15-3308
Open in Who Shared Issue with article?

PLOS ONE: Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice

|
By Susan P. Foy, Bavarian Nordic, Barbara Sennino, Tracy dela Cruz
| PLOS
Poxvirus-based active immunotherapies mediate anti-tumor efficacy by triggering broad and durable Th1 dominated T cell responses against the tumor. While monotherapy significantly delays tumor growth, it often does not lead to complete tumor regression. It was hypothesized that the induced robust infiltration of IFNγ-producing T cells into the tumor could provoke an adaptive immune evasive response by the tumor through the upregulation of PD-L1 expression.
Open in Who Shared Issue with article?
See all 3 articles